Business Description
Australian Clinical Labs Ltd
ISIN : AU0000148496
Total Employee Number:
4,700Description
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.07 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 2.09 | |||||
Debt-to-EBITDA | 1.75 | |||||
Interest Coverage | 18.27 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.43 | |||||
Beneish M-Score | -3.79 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -7.6 | |||||
3-Year EBITDA Growth Rate | -18.1 | |||||
3-Year EPS without NRI Growth Rate | -42.2 | |||||
3-Year FCF Growth Rate | -11.1 | |||||
3-Year Book Growth Rate | -8.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 4.82 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.61 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.76 | |||||
9-Day RSI | 58.18 | |||||
14-Day RSI | 59.19 | |||||
3-1 Month Momentum % | 18.52 | |||||
6-1 Month Momentum % | -17.95 | |||||
12-1 Month Momentum % | -18.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.59 | |||||
Quick Ratio | 0.5 | |||||
Cash Ratio | 0.12 | |||||
Days Inventory | 46.2 | |||||
Days Sales Outstanding | 40.67 | |||||
Days Payable | 109.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 5.31 | |||||
Dividend Payout Ratio | 0.88 | |||||
3-Year Dividend Growth Rate | 1.4 | |||||
Forward Dividend Yield % | 5.31 | |||||
5-Year Yield-on-Cost % | 5.25 | |||||
3-Year Average Share Buyback Ratio | 1 | |||||
Shareholder Yield % | 13.42 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 82.46 | |||||
Operating Margin % | 8.35 | |||||
Net Margin % | 3.6 | |||||
EBITDA Margin % | 24.6 | |||||
FCF Margin % | 21.43 | |||||
OCF Margin % | 22.5 | |||||
ROE % | 16.09 | |||||
ROA % | 4.58 | |||||
ROIC % | 6.38 | |||||
3-Year ROIIC % | 458.24 | |||||
ROC (Joel Greenblatt) % | 15.95 | |||||
ROCE % | 12.25 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 16.76 | |||||
Forward PE Ratio | 13.08 | |||||
PE Ratio without NRI | 16.76 | |||||
Price-to-Owner-Earnings | 2.78 | |||||
PS Ratio | 0.6 | |||||
PB Ratio | 3.03 | |||||
Price-to-Free-Cash-Flow | 2.81 | |||||
Price-to-Operating-Cash-Flow | 2.67 | |||||
EV-to-EBIT | 16.38 | |||||
EV-to-Forward-EBIT | 10.35 | |||||
EV-to-EBITDA | 4.09 | |||||
EV-to-Forward-EBITDA | 4.1 | |||||
EV-to-Revenue | 1 | |||||
EV-to-Forward-Revenue | 0.93 | |||||
EV-to-FCF | 4.62 | |||||
Price-to-GF-Value | 0.78 | |||||
Earnings Yield (Greenblatt) % | 6.11 | |||||
FCF Yield % | 35.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Australian Clinical Labs Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 731.336 | ||
| EPS (TTM) (A$) | 0.142 | ||
| Beta | 0.7992 | ||
| 3-Year Sharpe Ratio | -0.37 | ||
| 3-Year Sortino Ratio | -0.5 | ||
| Volatility % | 32.99 | ||
| 14-Day RSI | 59.19 | ||
| 14-Day ATR (A$) | 0.079078 | ||
| 20-Day SMA (A$) | 2.3145 | ||
| 12-1 Month Momentum % | -18.84 | ||
| 52-Week Range (A$) | 1.8325 - 2.97 | ||
| Shares Outstanding (Mil) | 186.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Australian Clinical Labs Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Australian Clinical Labs Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-10-23 09:00 | In 84 days | ||
| Annual report for 2026 | 2026-09-18 | In 48 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-08-26 10:00 | In 26 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-26 | In 25 days | ||
| AUD 0.037500 Cash Dividend | 2026-03-12 | 2.16 (-1.37%) | ||
| Second quarter earnings conference call for 2026 | 2026-02-16 12:30 | 2.42 (-0.82%) | ||
| Second quarter earnings results for 2026 | 2026-02-16 | 2.42 (-0.82%) | ||
| General meeting for 2025 | 2025-10-23 09:00 | 2.53 (-0.78%) | ||
| Annual report for 2025 | 2025-09-19 | 2.50 (-0.79%) | ||
| AUD 0.090000 Cash Dividend | 2025-09-01 | 2.85 (+2.15%) |
Show
Entries
Australian Clinical Labs Ltd Frequently Asked Questions
What is Australian Clinical Labs Ltd(ASX:ACL)'s stock price today?
The current price of ASX:ACL is A$2.38. The 52 week high of ASX:ACL is A$2.97 and 52 week low is A$1.83.
When is next earnings date of Australian Clinical Labs Ltd(ASX:ACL)?
The next earnings date of Australian Clinical Labs Ltd(ASX:ACL) is 2026-08-26 Est..
Does Australian Clinical Labs Ltd(ASX:ACL) pay dividends? If so, how much?
The Dividend Yield %  of Australian Clinical Labs Ltd(ASX:ACL) is 5.31% (As of Today), Highest Dividend Payout Ratio of Australian Clinical Labs Ltd(ASX:ACL) was 2.68. The lowest was 0.14. And the median was 0.78. The  Forward Dividend Yield % of Australian Clinical Labs Ltd(ASX:ACL) is 5.31%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Australian Clinical Labs Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers